Carrier-bound immunogenic determinants and carrier therefor

• US 4,894,229 A
• Filed: 04/21/1986
• Issued: 01/16/1990
• Est. Priority Date: 07/17/1981
• Status: Expired due to Fees

• Current Assignee: South African Inventions Development Corp.
• Original Assignee: South African Inventions Development Corp.
• Inventors: Polson, Alfred, Van der Merwe, Kirsten J.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US06/854,242
• Time in Patent Office: 1,366 Days
• Field of Search: 424/88, 424/92, 424/93, 424/85, 436/518, 436/519, 436/536, 436/532, 436/541, 436/819, 436/823, 435/4, 435/6, 435/7, 435/29, 435/253, 435/243, 435/820, 435/817, 435/245, 435/134, 435/132, 435/131, 435/176, 435/181, 435/174, 530/380, 530/810
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/521 inactivated (killed)
• CPC Class Codes: A61K 2039/6006 Cells recombinantly expressing antigens A61K2039/5156, A61K2039/523
• CPC Class Codes: A61K 39/385 Haptens or antigens, bound to carriers
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61K 47/6901 Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
• CPC Class Codes: C12N 1/005 after treatment of microbial biomass not covered by C12N1/02 - C12N1/08
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/554 the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10S 424/804 involving IgG3, IgG4, IgA, or IgY
• CPC Class Codes: Y10S 435/82 Subcellular parts of microorganisms
• CPC Class Codes: Y10S 530/81 Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Abstract

An immunogenicity increasing carrier substance for immunogenic determinants is composed of particles derived from gram-negative cells substantially devoid or depleted of their natural immunogenic determinants, more particularly prepared by stripping the O-antigen and core region off the lipid A by chemical cleavage (acid hydrolysis). These socalled "naked bacteria" are chemically treated with a linking reagent to provide covalently bonded intermediate linking moieties while preserving the adjuvant effect of the particles. The linking moieties have functional groups. These serve for the covalent bonding of selected haptens or antigens comprising the desired immunogenic determinants against which antibodies are to be elicited in living antibody-producing cells. Such carrier-bound immunogenic substance can be prepared in injectable form for immunizing fowls or mammals to induce protective immunization, or to produce specific antisera or to produce antibody preparations for diagnostic, forensic, pharmacokinetic and other tests.

Claims

1. A carrier substance for immunogenic determinants, comprising immunogenicity-increasing carrier particles derived from gram-negative bacterial cells substantially devoid or depleted of natural immunogenic determinants of the cells and comprising that region of the cells which includes lipid A and from there ranges inwardly towards the cell interior and including cell wall material, the particles having been chemically treated with a linking reagent in an amount to provide covalently bonded intermediate linking moieties exposed on the particles, providing reactive functional groups adapted to be bonded covalently to an immunogenically effective amount of selected haptens or immunogens comprising immunogenic determinants, while preserving the adjuvant character of the lipid A and cell wall material.

2. A carrier substance as claimed rn claim 1, wherein the particles are gram-negative bacterial cell particles subjected to chemical cleavage to substantially free the lipid A of 0-determinant-carrying material external of the lipid A, followed by covalent bonding to the particle exterior of the intermediate linking moieties.

3. A carrier substance as claimed in claim 2, wherein the cell walls of the cell particles are substantially intact.

4. A carrier substance as claimed in claim 2, wherein 80% or more of the natural O-antigens have been cleaved off.

5. A carrier substance as claimed in claim 4, wherein 90% or more of the natural O-antigens have been cleaved off.

6. A carrier substance as claimed in claim 5, wherein from 92 to 98% of the natural 0-antigens have been cleaved off.

7. A carrier substance as claimed in claim 1, wherein the linking reagent with which the particles have been treated is a bifunctional linking agent comprising two functional groups.

8. A carrier substance as claimed in claim 7, wherein the two functional groups of the bifunctional linking agent are the same.

9. A carrier substance as claimed in claim 7, wherein the two functional groups of the bifunctional linking agent are different.

10. A carrier substance as claimed in claim 7, wherein the functional groups are selected from the group consisting of aldehyde, imide, amino, cyano, halogen, activated carboxyl, carboxylic acid anhydride or a maleimide.

11. A carrier substance as claimed in claim 10, wherein the linking agent is a dialdehyde, diamine, cyanogen bromide, N-succinimidyl-3(N-succinimidyl)propionate, or a N-hydroxyorsuccimide ester of N-(-4-4-carboxy-cyclohexyl) maleimide.

12. A carrier substance as claimed in claim 1, wherein the linking moieties are present in an amount adapted to bond hapten or immunogen in excess of 1-2 μ

g/mg of particles on a dry mass basis.

13. A carrier substance as claimed in claim 12, so adapted to bond from 1 to about 200 μ

g hapten or immunogen per mg of particles on a dry mass basis.

14. A carrier substance as claimed in claim 1 which has been converted into an immunogenic substance in that the reactive functional groups have been reacted to covalently bond selected haptens or immunogens comprising immunogenic determinants for a desired immune response by antibodyproducing cells.

15. A carrier substance converted into an immunogenic substance according to claim 14 in the form of an injectable vaccine.

16. A carrier substance according to claim 14 to which has been covalently bonded hapten or immunogen in excess of 1-2 μ

g/mg of particles on a dry mass basis.

17. A carrier substance according to claim 14 to which has been covalently bonded from 1 to about 200 μ

g hapten or immunogen per mg of particles on a dry mass basis.

18. A carrier substance according to claim 14 to which has been covalently bonded 5-50 μ

g hapten or immunogen per mg of particles on a dry mass basis.

19. An immunogenic substance with inherent adjuvant properties, comprising carrier particles having an exterior surface, derived from gram-negative bacterial cells having a membrane including an outer periphery known as the cell wall and lipid A, which particles include the cell region ranging inwardly from lipid A to the membrane, both inclusive and from which particles any cell material beyond lipid A, including O-antigen has been removed by chemical cleavage whollyor predominantly and further comprising an immunogenic determinant for producing a desired immunogenic response in living, antibody-producing cells, the determinant being coalently bonded by a synthetic linking reaction to the exterior surface of the carrier particles in a form permitting immuno-recognition by antibody-producing cells, the immunogenic determinant containing immunogenic information which elicits a desired response and the adjuvant character of the particles being preserved.

20. A substance as claimed in claim 19, wherein 80% or more of the natural O-antigens have been cleaved off the particles.

21. A substance as claimed in claim 20, wherein 90% or more of the natural 0-antigens have been cleaved off.

22. A substance as claimed in claim 21, wherein from 92 to 98% of the natural, 0-antigens have been cleaved off.

23. An immunogenic substance according to claim 19, wherein the immunogenic determinant is bonded directly to the carrier bacterial particle.

24. An immunogenic substance according to claim 19, wherein the immunogenic determinant is bonded to the carrier bacterial particle via a bifunctional linking agent.

25. A substance as claimed in claim 24, wherein the two functional groups of the bifunctional linking agent are the same.

26. A substance as claimed in claim 24, wherein the two functional groups of the bifunctional linking agent are different.

27. A substance as claimed in claim 24, wherein the functional groups are selected from the group consisting of aldehyde, imide, amino, cyano, halogen, activated carboxyl, carboxylic acid anhydride or a maleimide.

28. A substance as claimed in claim 27, wherein the linking agent is a dialdehyde, diamine, cyanogen bromide, N- succinimidyl-3(N-succinimidyl)propionate, or a N-hydroxysuccinimide ester of N-(-4-4-carboxy-cyclohexyl)maleimide.

29. A substance as claimed in claim 19, wherein the cell walls of the cell particles are substantially intact.

30. A substance as claimed in claim 19, wherein the immunogenic determinant is foreign to the carrier bacterial particle.

31. A substance as claimed in claim 30, wherein the immunogeni determinant is an antibody.

32. A substance as claimed in claim 19, wherein the immunogenic determinant is provided by a hapten or antigen covalently bonded to the carrier particles in an amount in excess of 1-2 μ

g/mg of particles on a dry mass basis.

33. A substance as claimed in claim 32, comprising from 1 to about 200 μ

g hapten or immunogen per mg of particles on a dry mass basis.

34. A substance as claimed in claim 33, comprising 5-50 μ

g hapten or immunogen per mg of particles on a dry mass basis.

35. A substance as claimed in claim 34, comprising 5-20 μ

g hapten or immunogen per mg of particles on a dry mass basis.

36. A substance as claimed in claim 19, wherein the immunogenic determinant has a molecular weight of less than 150,000 Daltons.

37. A substance as claimed in claim 36, wherein the molecular weight is less than 100,000 Daltons.

38. A substance as claimed in claim 37, wherein the molecular weight is less than 30,000 Daltons.

39. A substance as claimed in claim 19 in the form of an immunogenic composition which elicits an immunogenic response for active protective immunisation against a disease or pathological condition, and which comprises an immunogeni determinant containing immunogenic information for producing the desired specific immunogenic response covalently bonded to the carrier particles.

40. In a method of raising antibodies against an immunogenic determinant which comprises challenging antibody-producing living cells with an immunogenic determinant, the improvement which comprises so challenging the cells with an immunogenic substance with inherent adjuvant properties, comprising immunogenicity-increasing carrier particles having an exterior surface, derived from gram-negative bacterial cells having a membrane including an outer periphery known as the cell wall and lipid A, which particles include the cell region ranging inwardly from lipid A to the membrane, both inclusive and from which particles any cell material beyond lipid A, including O-antigen has been removed by chemical cleavage wholly or predominantly and further comprising an immunogenic determinant for producing a desired immunogenic response in living, antibody-producing cells, the determinant being covalently bonded by a synthetic linking reaction to the exterior surface of the carrier particles in a form permitting immuno recognition by antibody-producing cells, the immunogenic determinant containing immunogenic information which elicits a desired response.

41. A method according to claim 40, which further comprises concentrating and recovering the antibodies raised.

42. A method according to claim 41, wherein the antibodies are incorporated in a composition for use as an anti-serum.

43. A method according to claim 41, wherein the antibodies are converted into or adapted to use as an immuno-reagent